We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

R-BIOPHARM

R-Biopharm AG is a biotechnology company that offers innovative products for numerous applications in the area of cli... read more Featured Products: More products

Download Mobile App




Molecular Assay Evaluated for Norovirus Detection

By LabMedica International staff writers
Posted on 03 Jul 2014
A commercial real-time polymerase chain reaction (RT-PCR) assay has been evaluated for the detection of noroviruses for use in a routine diagnostic laboratory. More...


The noroviruses (NoVs), which are now recognized as a major cause of both sporadic cases and outbreaks of gastroenteritis, are single-stranded positive-sense ribonucleic acid (RNA) viruses classified as the genus Norovirus within the family Caliciviridae.

Communicable disease specialists at the Victorian Infectious Diseases Reference Laboratory (Melbourne, Australia) tested 100 fecal specimens positive for NoV by open reading frames (ORF) 1 RT-PCR. A second group comprised of 100 fecal specimens negative for NoV by RT-PCR protocols. A third group comprised of 16 fecal specimens, which were selected as a specificity control to evaluate the assay for cross-reactivity to common fecal viruses other than NoV.

The commercial assay under evaluation was the RIDAGENE norovirus (NoV) real-time polymerase chain reaction assay (R-Biopharm; Darmstadt, Germany). The scientists found that the assay was straightforward to perform. For a run of 50 specimens, the PCR component took about one hour. Thus, with initial fecal processing and subsequent RNA extraction, a result could be obtained in roughly four hours for a run of 50 specimens. The RIDAGENE assay had an overall sensitivity of 98% but was more sensitive for GII than GI NoV and the assay had a specificity of 98%. The assay did not cross react with a number of gastroenteritis viruses including adenovirus, astrovirus, Rotavirus, and Sapovirus.

The author concluded that the RIDAGENE assay proved straightforward to use and time efficient. The assay had good sensitivity and specificity and can be recommended as a valuable detection method for NoV in a diagnostic laboratory. The study was published on the July 2014 edition of the journal Diagnostic Microbiology and Infectious Disease.

Related Links:

Victorian Infectious Diseases Reference Laboratory 
R-Biopharm



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.